21 September 2008 in Nature
The incidence of autoimmune diabetes in NOD (non-obese diabetic) mice, a lab model for type 1 diabetes, varies depending on the conditions in which they are kept. In particular, NOD mice exposed to killed mycobacteria and other microbial products are protected against the development of diabetes, suggesting the involvement of the rapid innate immune response. Experiments in NOD mice deficient in innate immunity — through the absence of the Toll-like receptor signal adaptor protein MyD88 — now show that both innate immunity and intestinal microbiota influence predisposition to diabetes. Germ-free MyD88-negative mice developed robust diabetes, yet in mice with a complement of gut microbes similar to the normal human gut, diabetes was reduced. This raises the prospect that live 'friendly' microbes, or microbial products might be therapeutic options for type 1 diabetes. The effect of deficiency of MyD88 on the generation of type 1 diabetes (T1D) has been investigated through the generation of congenic strains in the non-obese diabetic (NOD) mouse model. It is found that in specific pathogen-free conditions, MyD88-deficiency attenuates T1D, indicating that the interaction of intestinal microbes with the innate immune system is a critical factor in modifying susceptibility to type 1 diabetes. Type 1 diabetes (T1D) is a debilitating autoimmune disease that results from T-cell-mediated destruction of insulin-producing β-cells. Its incidence has increased during the past several decades in developed countries1,2, suggesting that changes in the environment (including the human microbial environment) may influence disease pathogenesis. The incidence of spontaneous T1D in non-obese diabetic (NOD) mice can be affected by the microbial environment in the animal housing facility3 or by exposure to microbial stimuli, such as injection with mycobacteria or various microbial products4,5. Here we show that specific pathogen-free NOD mice lacking MyD88 protein (an adaptor for multiple innate immune receptors that recognize microbial stimuli) do not develop T1D. The effect is dependent on commensal microbes because germ-free MyD88-negative NOD mice develop robust diabetes, whereas colonization of these germ-free MyD88-negative NOD mice with a defined microbial consortium (representing bacterial phyla normally present in human gut) attenuates T1D. We also find that MyD88 deficiency changes the composition of the distal gut microbiota, and that exposure to the microbiota of specific pathogen-free MyD88-negative NOD donors attenuates T1D in germ-free NOD recipients. Together, these findings indicate that interaction of the intestinal microbes with the innate immune system is a critical epigenetic factor modifying T1D predisposition.
1 July 2017 in The Journal of Nutrition
The gut microbiota is a complex community of bacteria residing in the intestine. Animal models have demonstrated that several factors contribute to a
3 December 2007 in Journal of Clinical Investigation
The precise roles of B cells in promoting the pathogenesis of type 1 diabetes remain undefined. Here, we demonstrate that B cell depletion in mice can prevent or delay diabetes, reverse diabetes after frank hyperglycemia, and lead to the development of cells that suppress disease. To determine the efficacy and potential mechanism of therapeutic B cell depletion, we generated a transgenic NOD mouse expressing human CD20 (hCD20) on B cells. A single cycle of treatment with an antibody specific for hCD20 temporarily depleted B cells and significantly delayed and/or reduced the onset of diabetes. Furthermore, disease established to the point of clinical hyperglycemia could be reversed in over one-third of diabetic mice. Why B cell depletion is therapeutic for a variety of autoimmune diseases is unclear, although effects on antibodies, cytokines, and antigen presentation to T cells are thought to be important. In B cell–depleted NOD mice, we identified what we believe is a novel mechanism by which B cell depletion may lead to long-term remission through expansion of Tregs and regulatory B cells. Our results demonstrate clinical efficacy even in established disease and identify mechanisms for therapeutic action that will guide design and evaluation of parallel studies in patients.
1 September 1999 in Nature Medicine
1 January 2016 in Journal of Autoimmunity
1 January 1996 in Journal of Experimental Medicine
T cells play an important role in the pathogenesis of diabetes in the nonobese diabetic (NOD) mouse. CD8 cytotoxic T cell lines and clones were generated from the lymphocytic infiltrate in the islets of Langerhans of young (7-wk-old). NOD mice by growing them on (NOD x B6-RIP-B7-1)F1 islets. These cells proliferate specifically to NOD islets and kill NOD islets in vitro. The cells are restricted by H-2Kd, and all bear T cell antigen receptor encoded by V beta 6. When these CD8 T cell lines and clones are adoptively transferred to irradiated female NOD, young NOD-SCID, and CB17-SCID mice, diabetes occurs very rapidly, within 10 d of transfer and without CD4 T cells.